Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C

World Journal of Gastroenterology

Volumn 13, Issue 8, 2007, Pages 1292-1294

  Soultati, Aspasia S ^a   Dourakis, Spyridon P ^a,b   Alexopoulou, Alexandra ^a   Deutsch, Melanie ^a   Archimandritis, Athanasios J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Autoimmune thyroiditis; Chronic hepatitis C; Insullin dependent diabetes mellitus; Pegylated interferon alpha

Indexed keywords

AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; GLUTAMATE DECARBOXYLASE; INSULIN; LIOTHYRONINE; PEGINTERFERON ALPHA2A; PROPRANOLOL; RIBAVIRIN; THYROGLOBULIN ANTIBODY; THYROID ANTIBODY; THYROID PEROXIDASE; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE; VIRUS RNA;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; CLINICAL FEATURE; DIABETIC KETOACIDOSIS; DISEASE COURSE; DRUG RESPONSE; DRUG WITHDRAWAL; FAMILY HISTORY; FEMALE; GENETIC PREDISPOSITION; HASHIMOTO DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HLA TYPING; HORMONE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIVER HISTOLOGY; THYROID FUNCTION TEST;

EID: 34247159134     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i8.1292     Document Type: Article

References (30)

1. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283-291
2. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38-47
3. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, Hadziyannis S. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997; 26: 206-210
4. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006; 43: 661-672
5. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003; 18: 549-558
6. Maede Y, Morishita K, Iwamura K, Takayama Y, Tsukada Y, Kishino M, Shimizu T, Matsushima S, Komatsu T, Kasagi Y. Chronic hepatitis C with early complication of Grave's disease during the treatment of pegylated interferon alpha-2a. Nippon Naika Gakkai Zasshi 2005; 94: 2600-2602
7. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699
8. Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989; 38: 641-647
9. Ishigami Y, Kanda T, Wada M, Shimizu Y. Glucose intolerance during interferon therapy in patients with chronic hepatitis type C. Nippon Rinsho 1994; 52: 1901-1904
10. Imano E, Kanda T, Ishigami Y, Kubota M, Ikeda M, Matsuhisa M, Kawamori R, Yamasaki Y. Interferon induces insulin resistance in patients with chronic active hepatitis C. J Hepatol 1998; 28: 189-193
11. Chatterjee S. Massive increase of insulin resistance in a patient with chronic hepatitis C after treatment with interferon. J Assoc Physicians India 2004; 52: 514
12. Ito Y, Takeda N, Ishimori M, Akai A, Miura K, Yasuda K. Effects of long-term interferon-alpha treatment on glucose tolerance in patients with chronic hepatitis C. J Hepatol 1999; 31: 215-220
13. Konrad T, Zeuzem S, Vicini P, Toffolo G, Briem D, Lormann J, Herrmann G, Berger A, Kusterer K, Teuber G, Cobelli C, Usadel KH. Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. Eur J Clin Invest 2000; 30: 111-121
14. Tai TY, Lu JY, Chen CL, Lai MY, Chen PJ, Kao JH, Lee CZ, Lee HS, Chuang LM, Jeng YM. Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C. J Endocrinol 2003; 178: 457-465
15. Devendra D, Eisenbarth GS. Interferon alpha-a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol 2004; 111: 225-233
16. Foulis AK. Interferon-alpha and IDDM: comment. Diabetologia 1996; 39: 127
17. Sasso FC, Carbonara O, Di Micco P, Coppola L, Torella R, Niglio A. A case of autoimmune polyglandular syndrome developed after interferon-alpha therapy. Br J Clin Pharmacol 2003; 56: 238-239
18. Christensen UB, Krogsgaard K. Onset of type 1 diabetes mellitus during combination therapy of chronic hepatitis C with interferon-alpha and ribavirin. Ugeskr Laeger 2004; 166: 1024-1025
19. Schories M, Peters T, Rasenack J, Reincke M. Autoantibodies against islet cell antigens and type 1 diabetes after treatment with interferon-alpha. Dtsch Med Wochenschr 2004; 129: 1120-1124
20. Radhakrishnan S, Upadhyay A, Mohan N, Dhar A, Walia HK, Zubaidi G. Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report. Med Princ Pract 2005; 14: 281-283
21. Jabr FI, Ordinario MM. Sudden onset of diabetic ketoacidosis during pegylated interferon alfa therapy. Am J Med 2003; 115: 158-159
22. Cozzolongo R, Betterle C, Fabris P, Paola Albergoni M, Lanzilotta E, Manghisi OG. Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 2006; 18: 689-692
23. Bosi E, Minelli R, Bazzigaluppi E, Salvi M. Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease? Diabet Med 2001; 18: 329-332
24. Bhatti A, McGarrity TJ, Gabbay R. Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C. Am J Gastroenterol 2001; 96: 604-605
25. Recasens M, Aguilera E, Ampurdanes S, Sanchez Tapias JM, Simo O, Casamitjana R, Conget I. Abrupt onset of diabetes during interferon-alpha therapy in patients with chronic hepatitis C. Diabet Med 2001; 18: 764-767
26. Mofredj A, Howaizi M, Grasset D, Licht H, Loison S, Devergie B, Demontis R, Cadranel JF. Diabetes mellitus during interferon therapy for chronic viral hepatitis. Dig Dis Sci 2002; 47: 1649-1654
27. Fabris P, Betterle C, Floreani A, Greggio NA, de Lazzari F, Naccarato R, Chiaramonte M. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992; 340: 548
28. Fabris P, Betterle C, Greggio NA, Zanchetta F, Bosi E, Biasin MR, de Lalla F. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998; 28: 514-517
29. Seifarth C, Benninger J, Bohm BO, Wiest-Ladenburger U, Hahn EG, Hensen J. Augmentation of the immune response to islet cell antigens with development of diabetes mellitus caused by interferon-alpha therapy in chronic hepatitis C. Z Gastroenterol 1999; 37: 235-239
30. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-718